Orgenesis Inc (ORGS) 0.4000 $ORGS
Orgenesis Delivers Poster Presentation at European Society of Gene and Cell Therapy (ESGCT) Congress
Marketwired - Fri Sep 18, 5:26PM CDT
Orgenesis Inc. (OTCQB: ORGS), a cell therapy and regenerative medicine company with a novel therapeutic technology dedicated to converting a patient's own cells into functioning insulin-producing cells as a treatment for diabetes, today announced it will present a poster session at the European Society of Gene and Cell Therapy (ESGCT) Congress held in Helsinki, Finland from September 17-20, 2015.
Orgenesis Featured in Special Report on Curing Diabetes
ACCESSWIRE - Wed Sep 09, 1:00AM CDT
NEW YORK, NY / ACCESSWIRE / September 9, 2015 / Orgenesis, Inc. (OTCQB:ORGS) and Scott Carmer the Company's U.S. CEO, is featured in the Special Report: Curing Diabetes. To view the segment please visit: https://www.youtube.com/watch?v=6JhXF0VIj50.
Farmers Embrace New Technology to Relieve Drought Pressure and Increase Fruit & Vegetable Quality/Quantity Using Less Water
GlobeNewswire - Thu Aug 13, 2:08AM CDT
via PRWEB - Xgenex LLC, a Ponte Vedra Beach Florida biotechnology business, has entered into a commercial agreement with microorganism innovation company AquaBella Organic Solutions, for the North American sales of AquaBella bio-enzyme water treatment and OMRI listed TerraBella organic sustainable soil corrective and root inoculant, that improve produce quality and increase yield in a variety of soils and climates while relieving drought pressure in hard-hit areas of North America.
Orgenesis Subsidiary MaSTherCell to Manufacture TxCell's Lead Product Ovasave for Multi-National Phase 2b Trial
Marketwired - Wed Jul 29, 10:22AM CDT
Orgenesis Inc. (OTCQB: ORGS), a cell therapy and regenerative medicine company with a novel therapeutic technology dedicated to converting a patient's own cells into functioning insulin-producing cells as a treatment for diabetes, today announced that its wholly owned subsidiary, MaSTherCell, a Contract Development and Manufacturing Organization (CDMO) has entered into a Memorandum of Understanding with France-based TxCell (Paris: TXCL) (Euronext Paris: FR0010127662 - TXCL), to manufacture clinical batches of Ovasave(R), TxCell's lead product. Ovasave is an antigen specific autologous T regulatory somatic cell therapy in development for the treatment of Inflammatory Bowel Disease. As part of the Memorandum of Understanding, MaSTherCell and TxCell also agreed to enter into discussions for the long-term clinical and commercial manufacturing by MaSTherCell of TxCell products.
StockNewsNow.com Publishes New SNNLive Video Interview With Orgenesis Inc.
Marketwired - Mon Jun 15, 7:30AM CDT
StockNewsNow.com, the Official MicroCap News Source, today published an SNNLive Video Interview with Vered Caplan, CEO of Orgenesis Inc. (OTCQB: ORGS), a cell therapy and regenerative medicine company that is committed to developing a cure for Type 1 Diabetes. The video interview was recorded at the B. Riley & Co. Investor Conference 2015 in Hollywood, CA.
Orgenesis to Present at 3rd Global Life Sciences Conference in Warsaw
Marketwired - Mon Jun 08, 7:00AM CDT
Orgenesis Inc. (OTCQB: ORGS), a cell therapy and regenerative medicine company with a novel therapeutic technology dedicated to converting a patient's own cells into functioning insulin-producing cells as a treatment for diabetes, today announced that the management of the Company will present at the upcoming 3rd Global Life Sciences Conference in Warsaw on Thursday, June 11, 2015 to be held on the trading floor of the Warsaw Stock Exchange, Warsaw, Poland. The Company's management will discuss technology innovations, future opportunities and progress in developing its potential cure for Type 1 diabetes by reprograming human liver cells into glucose-responsive, fully functional, Insulin Producing Cells (IPCs).
Orgenesis Founder Dr. Sarah Ferber to Present at American Diabetes Association's 75th Scientific Sessions
Marketwired - Fri Jun 05, 11:49AM CDT
Orgenesis Inc. (OTCQB: ORGS), a cell therapy and regenerative medicine company with a novel therapeutic technology dedicated to converting a patient's own cells into functioning insulin-producing cells as a treatment for diabetes, today announced that its founder and chief scientist, Dr. Sarah Ferber, will deliver a presentation at the American Diabetes Association's 75th Scientific Sessions.
Orgenesis Wins Deal of the Month by Acquisition International Magazine
Marketwired - Fri May 22, 11:42AM CDT
Orgenesis Inc. (OTCQB: ORGS), a cell therapy and regenerative medicine company with a novel therapeutic technology dedicated to converting a patient's own cells into functioning insulin-producing cells as a treatment for diabetes, today announced that its recent acquisition of MaSTherCell has been named "Deal of the Month" by Acquisitions International magazine.
Orgenesis to Present at the 16th Annual B. Riley Investor Conference
Marketwired - Thu May 07, 12:42PM CDT
Orgenesis Inc. (OTCQB: ORGS), a cell therapy and regenerative medicine company with a novel therapeutic technology dedicated to converting a patient's own cells into functioning insulin-producing cells as a treatment for diabetes, today announced that Ms. Vered Caplan, CEO of Orgenesis, will present on Tuesday, May 12th at 10:00 a.m. Pacific Time at the 16th Annual B. Riley & Co. Investor Conference to be held at the Loews Hollywood Hotel in Los Angeles, California from May 12 - 14, 2015. Ms. Caplan will be available for one-on-one meetings during the event.
Investment Fund Manager, Chris Buyse, Appointed to Orgenesis Board
Marketwired - Thu Apr 16, 9:00AM CDT
Orgenesis Inc. (OTCQB: ORGS), a cell therapy and regenerative medicine company with a novel therapeutic technology dedicated to converting a patient's own cells into functioning insulin-producing cells as a treatment for diabetes, today announced that Chris Buyse has been appointed to the Orgenesis board of directors.
CEO of MaSTherCell, Hugues Bultot, Joins Orgenesis Board of Directors
Marketwired - Wed Apr 15, 9:00AM CDT
Orgenesis Inc. (OTCQB: ORGS) a cell therapy and regenerative medicine company with a novel therapeutic technology dedicated to converting a patient's own liver cells into functioning insulin-producing cells as a treatment for diabetes, today announced the appointment of Hugues Bultot to its board of directors.
PLL: 127.11 (-0.01)
Orgenesis Signs Cell Therapy Product Development Memorandum of Understanding with CureCell of Korea
Marketwired - Wed Apr 08, 12:25PM CDT
Orgenesis Ltd., a wholly-owned subsidiary of Orgenesis Inc. (OTCQB: ORGS), a cell therapy and regenerative medicine company with a novel therapeutic technology dedicated to converting a patient's own cells into functioning insulin-producing cells as a treatment for diabetes, today announced it has entered a non-binding memorandum of understanding (MOU) with Korean company CureCell Co., Ltd.
Orgenesis to Collaborate With the Global Stem Cell & Regenerative Medicine Acceleration Center of Korea
Marketwired - Tue Apr 07, 1:27PM CDT
Orgenesis Inc. (OTCQB: ORGS) a cell therapy and regenerative medicine company with a novel therapeutic technology dedicated to converting a patient's own liver cells into functioning insulin-producing cells as a treatment for diabetes, today announced it has signed a collaboration (MOU) with the Global Stem Cell & Regenerative Medicine Acceleration Center (GSRAC) commissioned by Ministry of Health and Welfare of Korea.
Orgenesis Appoints Itamar Raz as Newest Member of Board of Advisors
Marketwired - Mon Mar 16, 7:00AM CDT
Orgenesis Inc. (OTCQB: ORGS) a development-stage company with a novel therapeutic technology dedicated to converting a patient's own liver cells into functioning insulin-producing cells as a treatment for diabetes, today announced that Professor Itamar Raz has been appointed to the Orgenesis board of advisors.
Organesis acquires Belgian cell therapy manufacturer
Seeking Alpha - at Seeking Alpha - Mon Mar 09, 9:05AM CDT
Orgenesis Acquires Cell Therapy Manufacturer MaSTherCell
Marketwired - Mon Mar 09, 5:00AM CDT
Orgenesis Inc. (OTCQB: ORGS) ("Orgenesis" or the "Company"
, a leader in the emerging fields of cellular therapy and re-generative medicine for the treatment of Type 1 Diabetes, today announced the Company's plan to increase its global presence and capabilities by acquiring MaSTherCell, an emerging pioneer in the industrialization of cell-based therapeutics, based in Gosselies, Belgium.
Orgenesis and Pall Corporation Receive $800,000 Grant From BIRD Foundation for Diabetes Research and Development
Marketwired - Mon Jan 26, 7:49AM CST
Orgenesis Ltd., a wholly-owned subsidiary of Orgenesis Inc. (OTCQB: ORGS), a leader in the emerging fields of cellular therapy and regenerative medicine, today announced that Orgenesis and Pall Corporation have received an $800,000 grant from the Israel-U.S. Binational Industrial Research and Development ("BIRD" Foundation to finance their current $1,600,000 co-development program.
PLL: 127.11 (-0.01)
Orgenesis Approved for EUR 2.015.000 Grant to Support Development of Its Type 1 Diabetes Program in Europe
Marketwired - Mon Nov 24, 2:21PM CST
Orgenesis SPRL, a subsidiary of Orgenesis Inc. (OTCQB: ORGS), a leader in the emerging fields of cellular therapy and regenerative medicine, today announced that it has received the formal approval from the Walloon Region, Belgium (Service Public of Wallonia, DG06) for a EUR 2,015 million support program for the research and development of a potential cure for Type 1 Diabetes.
Orgenesis Receives Patent for Potential Cure for Type 1 Diabetes
Marketwired - Wed Oct 15, 6:01AM CDT
Orgenesis Inc. (OTCQB: ORGS), a leader in the emerging fields of cellular therapy and regenerative medicine, today announced that it has received a patent for the technology supporting its unique cell-based therapy, which is being developed as a potential cure for Type 1 Diabetes. The U.S. patent No. 8,778,899, was granted for "Methods of Inducing Regulated Pancreatic Hormone Production in Non-pancreatic Islet Tissues" and recognizes the pioneering work done by Dr. Sarah Ferber and the research team at Orgenesis who have used the technology to successfully reprogram human liver cells into glucose-responsive, fully functional Insulin Producing Cells (IPCs).
Orgenesis Delivers Poster Presentation at European Society of Gene and Cell Therapy (ESGCT) Congress
Marketwired - Fri Sep 18, 5:26PM CDT
Orgenesis Inc. (OTCQB: ORGS), a cell therapy and regenerative medicine company with a novel therapeutic technology dedicated to converting a patient's own cells into functioning insulin-producing cells as a treatment for diabetes, today announced it will present a poster session at the European Society of Gene and Cell Therapy (ESGCT) Congress held in Helsinki, Finland from September 17-20, 2015.
Orgenesis Featured in Special Report on Curing Diabetes
ACCESSWIRE - Wed Sep 09, 1:00AM CDT
NEW YORK, NY / ACCESSWIRE / September 9, 2015 / Orgenesis, Inc. (OTCQB:ORGS) and Scott Carmer the Company's U.S. CEO, is featured in the Special Report: Curing Diabetes. To view the segment please visit: https://www.youtube.com/watch?v=6JhXF0VIj50.
Farmers Embrace New Technology to Relieve Drought Pressure and Increase Fruit & Vegetable Quality/Quantity Using Less Water
GlobeNewswire - Thu Aug 13, 2:08AM CDT
via PRWEB - Xgenex LLC, a Ponte Vedra Beach Florida biotechnology business, has entered into a commercial agreement with microorganism innovation company AquaBella Organic Solutions, for the North American sales of AquaBella bio-enzyme water treatment and OMRI listed TerraBella organic sustainable soil corrective and root inoculant, that improve produce quality and increase yield in a variety of soils and climates while relieving drought pressure in hard-hit areas of North America.
Orgenesis Subsidiary MaSTherCell to Manufacture TxCell's Lead Product Ovasave for Multi-National Phase 2b Trial
Marketwired - Wed Jul 29, 10:22AM CDT
Orgenesis Inc. (OTCQB: ORGS), a cell therapy and regenerative medicine company with a novel therapeutic technology dedicated to converting a patient's own cells into functioning insulin-producing cells as a treatment for diabetes, today announced that its wholly owned subsidiary, MaSTherCell, a Contract Development and Manufacturing Organization (CDMO) has entered into a Memorandum of Understanding with France-based TxCell (Paris: TXCL) (Euronext Paris: FR0010127662 - TXCL), to manufacture clinical batches of Ovasave(R), TxCell's lead product. Ovasave is an antigen specific autologous T regulatory somatic cell therapy in development for the treatment of Inflammatory Bowel Disease. As part of the Memorandum of Understanding, MaSTherCell and TxCell also agreed to enter into discussions for the long-term clinical and commercial manufacturing by MaSTherCell of TxCell products.
StockNewsNow.com Publishes New SNNLive Video Interview With Orgenesis Inc.
Marketwired - Mon Jun 15, 7:30AM CDT
StockNewsNow.com, the Official MicroCap News Source, today published an SNNLive Video Interview with Vered Caplan, CEO of Orgenesis Inc. (OTCQB: ORGS), a cell therapy and regenerative medicine company that is committed to developing a cure for Type 1 Diabetes. The video interview was recorded at the B. Riley & Co. Investor Conference 2015 in Hollywood, CA.
Orgenesis to Present at 3rd Global Life Sciences Conference in Warsaw
Marketwired - Mon Jun 08, 7:00AM CDT
Orgenesis Inc. (OTCQB: ORGS), a cell therapy and regenerative medicine company with a novel therapeutic technology dedicated to converting a patient's own cells into functioning insulin-producing cells as a treatment for diabetes, today announced that the management of the Company will present at the upcoming 3rd Global Life Sciences Conference in Warsaw on Thursday, June 11, 2015 to be held on the trading floor of the Warsaw Stock Exchange, Warsaw, Poland. The Company's management will discuss technology innovations, future opportunities and progress in developing its potential cure for Type 1 diabetes by reprograming human liver cells into glucose-responsive, fully functional, Insulin Producing Cells (IPCs).
Orgenesis Founder Dr. Sarah Ferber to Present at American Diabetes Association's 75th Scientific Sessions
Marketwired - Fri Jun 05, 11:49AM CDT
Orgenesis Inc. (OTCQB: ORGS), a cell therapy and regenerative medicine company with a novel therapeutic technology dedicated to converting a patient's own cells into functioning insulin-producing cells as a treatment for diabetes, today announced that its founder and chief scientist, Dr. Sarah Ferber, will deliver a presentation at the American Diabetes Association's 75th Scientific Sessions.
Orgenesis Wins Deal of the Month by Acquisition International Magazine
Marketwired - Fri May 22, 11:42AM CDT
Orgenesis Inc. (OTCQB: ORGS), a cell therapy and regenerative medicine company with a novel therapeutic technology dedicated to converting a patient's own cells into functioning insulin-producing cells as a treatment for diabetes, today announced that its recent acquisition of MaSTherCell has been named "Deal of the Month" by Acquisitions International magazine.
Orgenesis to Present at the 16th Annual B. Riley Investor Conference
Marketwired - Thu May 07, 12:42PM CDT
Orgenesis Inc. (OTCQB: ORGS), a cell therapy and regenerative medicine company with a novel therapeutic technology dedicated to converting a patient's own cells into functioning insulin-producing cells as a treatment for diabetes, today announced that Ms. Vered Caplan, CEO of Orgenesis, will present on Tuesday, May 12th at 10:00 a.m. Pacific Time at the 16th Annual B. Riley & Co. Investor Conference to be held at the Loews Hollywood Hotel in Los Angeles, California from May 12 - 14, 2015. Ms. Caplan will be available for one-on-one meetings during the event.
Investment Fund Manager, Chris Buyse, Appointed to Orgenesis Board
Marketwired - Thu Apr 16, 9:00AM CDT
Orgenesis Inc. (OTCQB: ORGS), a cell therapy and regenerative medicine company with a novel therapeutic technology dedicated to converting a patient's own cells into functioning insulin-producing cells as a treatment for diabetes, today announced that Chris Buyse has been appointed to the Orgenesis board of directors.
CEO of MaSTherCell, Hugues Bultot, Joins Orgenesis Board of Directors
Marketwired - Wed Apr 15, 9:00AM CDT
Orgenesis Inc. (OTCQB: ORGS) a cell therapy and regenerative medicine company with a novel therapeutic technology dedicated to converting a patient's own liver cells into functioning insulin-producing cells as a treatment for diabetes, today announced the appointment of Hugues Bultot to its board of directors.
PLL: 127.11 (-0.01)
Orgenesis Signs Cell Therapy Product Development Memorandum of Understanding with CureCell of Korea
Marketwired - Wed Apr 08, 12:25PM CDT
Orgenesis Ltd., a wholly-owned subsidiary of Orgenesis Inc. (OTCQB: ORGS), a cell therapy and regenerative medicine company with a novel therapeutic technology dedicated to converting a patient's own cells into functioning insulin-producing cells as a treatment for diabetes, today announced it has entered a non-binding memorandum of understanding (MOU) with Korean company CureCell Co., Ltd.
Orgenesis to Collaborate With the Global Stem Cell & Regenerative Medicine Acceleration Center of Korea
Marketwired - Tue Apr 07, 1:27PM CDT
Orgenesis Inc. (OTCQB: ORGS) a cell therapy and regenerative medicine company with a novel therapeutic technology dedicated to converting a patient's own liver cells into functioning insulin-producing cells as a treatment for diabetes, today announced it has signed a collaboration (MOU) with the Global Stem Cell & Regenerative Medicine Acceleration Center (GSRAC) commissioned by Ministry of Health and Welfare of Korea.
Orgenesis Appoints Itamar Raz as Newest Member of Board of Advisors
Marketwired - Mon Mar 16, 7:00AM CDT
Orgenesis Inc. (OTCQB: ORGS) a development-stage company with a novel therapeutic technology dedicated to converting a patient's own liver cells into functioning insulin-producing cells as a treatment for diabetes, today announced that Professor Itamar Raz has been appointed to the Orgenesis board of advisors.
Organesis acquires Belgian cell therapy manufacturer
Seeking Alpha - at Seeking Alpha - Mon Mar 09, 9:05AM CDT
Orgenesis Acquires Cell Therapy Manufacturer MaSTherCell
Marketwired - Mon Mar 09, 5:00AM CDT
Orgenesis Inc. (OTCQB: ORGS) ("Orgenesis" or the "Company"
, a leader in the emerging fields of cellular therapy and re-generative medicine for the treatment of Type 1 Diabetes, today announced the Company's plan to increase its global presence and capabilities by acquiring MaSTherCell, an emerging pioneer in the industrialization of cell-based therapeutics, based in Gosselies, Belgium. Orgenesis and Pall Corporation Receive $800,000 Grant From BIRD Foundation for Diabetes Research and Development
Marketwired - Mon Jan 26, 7:49AM CST
Orgenesis Ltd., a wholly-owned subsidiary of Orgenesis Inc. (OTCQB: ORGS), a leader in the emerging fields of cellular therapy and regenerative medicine, today announced that Orgenesis and Pall Corporation have received an $800,000 grant from the Israel-U.S. Binational Industrial Research and Development ("BIRD"
Foundation to finance their current $1,600,000 co-development program. PLL: 127.11 (-0.01)
Orgenesis Approved for EUR 2.015.000 Grant to Support Development of Its Type 1 Diabetes Program in Europe
Marketwired - Mon Nov 24, 2:21PM CST
Orgenesis SPRL, a subsidiary of Orgenesis Inc. (OTCQB: ORGS), a leader in the emerging fields of cellular therapy and regenerative medicine, today announced that it has received the formal approval from the Walloon Region, Belgium (Service Public of Wallonia, DG06) for a EUR 2,015 million support program for the research and development of a potential cure for Type 1 Diabetes.
Orgenesis Receives Patent for Potential Cure for Type 1 Diabetes
Marketwired - Wed Oct 15, 6:01AM CDT
Orgenesis Inc. (OTCQB: ORGS), a leader in the emerging fields of cellular therapy and regenerative medicine, today announced that it has received a patent for the technology supporting its unique cell-based therapy, which is being developed as a potential cure for Type 1 Diabetes. The U.S. patent No. 8,778,899, was granted for "Methods of Inducing Regulated Pancreatic Hormone Production in Non-pancreatic Islet Tissues" and recognizes the pioneering work done by Dr. Sarah Ferber and the research team at Orgenesis who have used the technology to successfully reprogram human liver cells into glucose-responsive, fully functional Insulin Producing Cells (IPCs).
